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j ourna l homepage: www.eb iomed ic ine.comEditorialProgress and Roadblocks Along the Pathway to Multiple Sclerosis TreatmentMarch 2–8 marked Multiple Sclerosis (MS) Awareness Week in the
United States MS is a chronic, often debilitating disease of the central
nervous system (CNS), affectingmore than 2million peopleworldwide.
As recently as 25 years ago, a diagnosis of MS came with no hope for
course-altering treatment options, and researchers had only a very
limited understanding of the mechanistic underpinnings of disease
onset or progression.
The etiology of the disease is still not completely understood—
although we do know that MS is effectively an autoimmune disease,
whereby the immune system launches an attack on the protective my-
elin sheath surrounding nerve cells. Loss of myelin prevents nerves
from signaling to each other normally, which in turn affects the ability
of the brain to send instructions to the body. This may lead to a wide
range of symptomsand outcomes of variable severity—including numb-
ness or weakness in one or more limbs, loss of normal motor function,
and emotional and cognitive effects. Most MS patients will initially ex-
perience a relapsing–remitting form of the disease (RRMS), whereby
sporadic ﬂare-ups of symptoms are followed by periods of remission.
A proportion of MS patients experience one of several progressive
forms of the disease characterized by worsening symptoms without
periods of remission—either from the onset of diagnosis, or after an
initial period of RRMS.
Why do the immune systems of patients with MS malfunction?
Although this is not entirely clear, and the initial antigen responsible
for triggering the immune response—whether it be of self- or foreign
pathogen-origin—has not been identiﬁed, we do know that genetic
and environmental factors are contributing factors to the disease.
Genome-wide association studies have recently identiﬁed at least 100
gene polymorphisms associated with MS risk—and most genes identi-
ﬁed seem to be related to immune system function. However—as with
other diseaseswith complicated etiology—genetics do not provide abso-
lute causality, and it seems environmental factors including, for exam-
ple, Epstein–Barr virus infection and smoking may also affect MS risk.
We know that T cells are involved in regulating the pathology of MS.
However, the precise roles of different T helper (Th) cell subtypes (such
as Th17 cells and regulatory T cells) and how these cells are themselves
regulated is not very clear. B cells are also thought to be involved: several
trials using B-cell blocking antibodies (such as ocrelizumab and
ofatumumab) have shown a reduction in disease severity for RRMS
and/or primary-progressive forms of MS. Questions remain, however,
regarding how B cells may be contributing to disease—for example
whether they may be presenting speciﬁc antigens or whether antibody
production may play a role.
The immune system and the regulatory factors that affect immune-
mediated inﬂammation are central factors in MS. Many treatment ap-
proaches for RRMS that are now available have focused on modulating
the immune system and blocking or reducing CNS inﬂammation. In
the early 1990s, interferon-β (IFN-β) was approved by the Food andhttp://dx.doi.org/10.1016/j.ebiom.2015.03.006
2352-3964/© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NCDrug Administration as one of the ﬁrst treatment options for relapsing
MS, and follow-up studies have indicated a reduction in relapse rates
aswell as disease severity for a proportion of IFN-β-treatedMS patients.
However, IFN-β treatment outcomes are variable among populations,
and we still have little mechanistic understanding of how this and
other immune modulators currently in use (such as glatiramer acetate
and dimethyl fumarate) ameliorateMS disease symptoms. Today, in ad-
dition to the immune modulators listed above, several biologics and
small molecules are in use or undergoing trials for the treatment of
MS. Examples include natalizumab and ﬁngolimod, which both block
the trafﬁc of T cells into the CNS bydifferentmechanisms, andwhich ap-
pear to be some of the more efﬁcacious therapeutics available.
Alemtuzumab, which depletes lymphocytes, has also recently been ap-
proved for RRMS. However, as this antibody will remove several types
of immune cells non-speciﬁcally, it is difﬁcult to pinpoint exactly how
it is working to reduce relapse rates.
Other clinical approaches to treating MS are focusing on addressing
the neurodegenerative component of the disease. For example, several
clinical trials are currently underway using a patient's own stem cells
to help repair damaged neurons, and to help ameliorate disease symp-
toms. Other researchers are also working to identify molecules or bio-
logics that may help to stimulate the repair of the myelin sheath.
Despite this encouraging progress, better insight into the cellular
mediators and regulators ofMS disease onset and progression is needed
in order to provide greater therapeutic speciﬁcity, to improve response
rates, and to help minimize adverse effects, which—for some
treatments—can potentially be quite severe. There is a pressing need
in particular for insight into pathological mechanisms underlying the
progressive form of MS, as most available treatment options in use or
under development are targeted toward relieving the relapsing form
of disease. However, one of the major challenges facing basic re-
searchers in this ﬁeld is the fact that—although powerful and widely
used—the most frequently used animal model system, experimental
autoimmune encephalomyelitis (EAE), does not fully recapitulate the
complex biology seen in human MS. The EAE disease model therefore
comes with some substantial caveats for probing disease mechanisms
and predicting the success of therapeutic interventions. Better, more
accurate, disease models are therefore needed.
There is also an urgent need for biomarkers which will help clinicians
easily diagnose MS, monitor disease progress, and responses to treat-
ment. Although a large number of biomarkers have been proposed for
MS, very fewhave been rigorously validated or applied to clinical practice.
We have come a long way in just the past few decades in both
understanding the basic molecular and cellular basis of disease, as
well as in developing several treatment approaches to managing dis-
ease severity. A diagnosis of MS now comes with some hope for
disease-altering treatment. But we still have a long way to go.-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).EBioMedicine
